Adaptimmune Therapeutics plc (ADAP) financial statements (2021 and earlier)

Company profile

Business Address 60 JUBILEE AVENUE
ABINGDON, OXFORDSHIRE, OX14 4RX
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments36890205208159
Cash and cash equivalents57506884159
Short-term investments31139137124 
Receivables212118121
Prepaid expense6866 
Other current assets1000 
Other undisclosed current assets211438
Total current assets:398120231230199
Noncurrent Assets
Operating lease, right-of-use asset1921
Property, plant and equipment2831364128
Intangible assets, net (including goodwill)22111
Intangible assets, net (excluding goodwill)22111
Restricted cash and investments54444
Other undisclosed noncurrent assets 3453
Total noncurrent assets:5361465136
TOTAL ASSETS:451182277281235
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3330141916
Accounts payable664811
Accrued liabilities272324 
Employee-related liabilities  875
Deferred revenue32
Debt 2   
Due to related parties   00
Deferred revenue and credits3911
Other liabilities  001
Other undisclosed current liabilities3 101612
Total current liabilities:3934247440
Noncurrent Liabilities
Long-term debt and lease obligation2123   
Operating lease, liability2123
Liabilities, other than long-term debt5015425
Deferred revenue and credits 25
Deferred revenue49 
Other liabilities1154 
Other undisclosed noncurrent liabilities    3
Total noncurrent liabilities:71245428
Total liabilities:11058307868
Stockholders' equity
Stockholders' equity attributable to parent341124247203166
Common stock11111
Additional paid in capital936586574455341
Accumulated other comprehensive loss(10)(7)(10)(22)(14)
Accumulated deficit(586)(456)(318)(232)(161)
Total stockholders' equity:341124247203166
TOTAL LIABILITIES AND EQUITY:451182277281235

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenue, net3814
Gross profit:41603814
Operating expenses(137)(141)(142)(118)(87)
Operating loss:(133)(140)(82)(81)(73)
Nonoperating income (expense)13(13)111
Investment income, nonoperating 332 
Other nonoperating income (expense)10(16)91
Loss from continuing operations before equity method investments, income taxes:(132)(137)(95)(70)(72)
Other undisclosed income from continuing operations before income taxes2   1
Loss from continuing operations before income taxes:(130)(137)(95)(70)(71)
Income tax expense(0)(0)(0)(0)(1)
Net loss available to common stockholders, diluted:(130)(137)(96)(70)(72)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(130)(137)(96)(70)(72)
Comprehensive loss:(130)(137)(96)(70)(72)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(3)212(7)(6)
Comprehensive loss, net of tax, attributable to parent:(133)(135)(84)(78)(78)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: